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a b s t r a c t
The contest between the host factor APOBEC3G (A3G) and the HIV-1 protein Vif presents an attractive
target of intervention. The extent to which the A3G–Vif interaction must be suppressed to tilt the balance
in favor of A3G remains unknown. We employed stochastic simulations and mathematical modeling of
the within-host dynamics and evolution of HIV-1 to estimate the fraction of progeny virions that must
incorporate A3G to render productive infection unsustainable. Using three different approaches, we
found consistently that a transition from sustained infection to suppression of productive infection
occurred when the latter fraction exceeded 0.8. The transition was triggered by A3G-induced
hypermutations that led to premature stop codons compromising viral production and was consistent
with driving the basic reproductive number, R0, below unity. The fraction identiﬁed may serve as a
quantitative guideline for strategies targeting the A3G–Vif axis.
& 2013 Elsevier Inc. All rights reserved.
Introduction
The host protein APOBEC3G (A3G), a cytidine deaminase,
induces signiﬁcant GG-to-AG hypermutations in HIV-1, which in
the absence of the HIV-1 protein Vif dramatically inhibit infection
in vitro (Malim, 2009). Vif targets A3G for proteasomal degrada-
tion, suppressing hypermutations and allowing persistent infec-
tion. The A3G–Vif interaction is thus a remarkable example of the
evolutionary arms race between retroviruses and their hosts
(Compton et al., 2012) and a promising target of intervention
(Dapp et al., 2012; Harris and Liddament, 2004). Indeed, several
candidate drug molecules targeting the A3G–Vif axis are currently
under development (Cen et al., 2010; Dapp et al., 2012; Ejima et al.,
2011; Nathans et al., 2008). The extent to which the A3G–Vif
interaction must be blocked in order to tilt the balance in favor of
A3G, however, remains unknown.
A3G-induced hypermutations may result in premature stop codons
that potentially suppress the production of infectious progeny virions.
For instance, the codon for tryptophan (TGG) can be converted to a
stop codon (TAG). Although proviral DNA sequences often show
high levels of hypermutation (Keele et al., 2008; Kieffer et al., 2005;
Land et al., 2008; Piantadosi et al., 2009), the proportion of viral RNA
sequences carrying extensive hypermutations in peripheral blood is
small (Kieffer et al., 2005; Land et al., 2008), suggesting that the
production of virions containing genomes with hypermutations/stop
codons may be suppressed (Kieffer et al., 2005; Russell et al., 2009).
In agreement, in vitro studies detected progressively fewer genomes
with hypermutations in going from proviral DNA to cellular RNA and
viral RNA, indicating a strong bias against packaging genomes with
extensive hypermutations into progeny virions (Russell et al., 2009).
As the fraction of virions carrying A3G rises, the resulting reduction
in the pool of infectious virions may render productive infection
unsustainable.
A3G molecules expressed in HIV-1-infected cells are incorpo-
rated into budding virions. In the absence of Vif, between 4 and 26
A3G units are estimated to be packaged per virion (Armitage et al.,
2012; Browne et al., 2009; Nowarski et al., 2008; Xu et al., 2007).
Vif appears to restrict A3G incorporation to 0.3–0.8 units/virion
(Nowarski et al., 2008), potentially ensuring that an adequate
number of virions that do not carry A3G is produced, which can
productively infect cells and sustain infection. Candidate drug
molecules targeting the A3G–Vif axis either suppress Vif, upregu-
late A3G expression or activity, or block the interaction of Vif and
A3G (Cen et al., 2010; Dapp et al., 2012; Ejima et al., 2011; Nathans
et al., 2008), in each case resulting effectively in an increased
fraction of budding virions incorporating A3G. Our goal therefore
was to identify the minimum fraction of progeny virions that must
incorporate A3G in order to render productive HIV-1 infection
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unsustainable. We employed stochastic simulations and mathe-
matical modeling to identify this critical fraction.
Results
Our simulations mimicked the within-host dynamics of pro-
ductive HIV-1 infection using a population genetics framework.
The simulations have been shown previously to capture HIV-1
diversiﬁcation in patients quantitatively (Balagam et al., 2011;
Vijay et al., 2008). Here, we modiﬁed the simulations to account
for the inﬂuence of intervention at the A3G–Vif axis. Brieﬂy, we
created an initial pool of virions, each carrying 2 copies of the full-
length HIV-1 genome (9073 nucleotides; GenBank: JN024117.1).
A fraction a of the virions was assumed to carry A3G. We selected
virions randomly from this pool and synchronously infected a pool
of uninfected cells. The viral RNAwas then reverse transcribed into
proviral DNA, during which process mutation and recombination
occurred. When an infecting virion contained A3G, hypermuta-
tions were also introduced at a rate dependent on the position on
the genome, following the twin-gradient hypermutation pattern
observed experimentally (Kijak et al., 2008; Suspene et al., 2006;
Yu et al., 2004). The resulting mutated, recombined, and hyper-
mutated proviral DNA in each cell were then transcribed into viral
RNA, which were assorted into pairs and released as progeny
virions. A fraction a of the progeny virions was again assumed to
carry A3G. The progeny virions formed the new viral pool from
which virions were chosen according to their relative ﬁtness for
the infection of a fresh set of uninfected cells, and the cycle was
repeated (Fig. 1). We tracked the evolution of the sizes of infected
cell and viral pools and the accumulation of mutations with time
(or generations) and averaged these quantities over many realiza-
tions. Supplementary material S1 contains details of the simula-
tion procedure and the parameter values employed. We examined
the implications of increasing a on the sustainability of infection.
Interestingly, we found a sharp transition from sustained infection
to complete suppression of infection as awas increased. With ao0:8
the size of the infected cell pool remained nearly constant indicating
sustained infection (Fig. 2A). As a increased to 0.8 and beyond,
the population decreased and eventually vanished, marking the
extinction of infection. We identiﬁed the critical fraction of virions
that must incorporate A3G as ac  0:81 as that value of a beyond
which infection went extinct in 490% of the realizations in our
simulations. The time for infection to be driven extinct reduced
exponentially as a increased beyond ac (Fig. 2B).
We validated this estimate of ac in 2 independent ways, namely,
using a population genetics-based mathematical model and using
the basic model of viral dynamics. Using simulations we deduced
that the impact of A3G on the sustainability of infection was
determined primarily by the induction of premature stop codons;
other factors, such as mutation, recombination, and ﬁtness penalties
associated with hypermutations that did not result in stop codons,
had only a minor inﬂuence (Supplementary material S2; Fig. S1).
Accordingly, we constructed a population genetics-based mathema-
tical model that explicitly accounted for the impact of A3G-induced
stop codons on the population of productively infected cells and
hence on the sustainability of infection (Supplementary material S3).
The model yielded
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indicating that ac depended on the position-dependent hypermuta-
tion rate, μh li
 
, where li is the position of the ith of the s potential
stop codon sites on the viral genome; the arithmetic and harmonic
means, Mh i and 1=M , respectively, of the number of infections/cell;
the number of progeny virions/cell, P; and the mean relative ﬁtness
of the progeny viral pool, f
 
. Scanning the full-length HIV-1 genome
employed in our simulations for loci where GG-to-AG hypermuta-
tions would lead to stop codons (e.g., TGG sites), we found that the
genome contained s 102 such potential stop codon sites, which
with the position-dependent hypermutation rate, μh l
 
, implied
∏si ¼ 1 1μh li
  
o103. (We examined three other HIV-1 genomes,
viz., GenBank: JN397362.1, JQ403032.1 and JF320530.1, and found a
similar number of potential stop codon sites). We obtained Mh i and
1=M
 
from the distribution of the frequency of multiple infections
employed in our simulations (Supplementary material S1), which
mimics recent experimental observations suggesting that a majority
of infected cells is singly infected (Josefsson et al., 2011; Schultz
et al., 2012).
Fig. 1. Schematic of the progression of infection and the inﬂuence of A3G. Viral particles with a ﬁxed fraction containing A3G (triangles) infect cells. The resulting proviral
DNA can contain stop codons (crosses) if the infecting virion contains A3G. Proviral DNA containing stop codons do not yield infectious progeny virions. When the fraction of
virions containing A3G is small, infection is sustained (left), whereas when it crosses a critical value, infection dies out (right).
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To estimate f
 
, we employed the structure of the quasispecies
predicted by our simulations as a approached ac . The quasispecies
displayed a bimodal structure, with peaks at Hamming classes
20 and 60 (Fig. 2C). The 2 peaks represented the 2 kinds of
viral particles in the viral pool, one carrying A3G and the other not.
Genomes from the former virions suffered hypermutations upon
infecting cells, whereas genomes from the latter did not. Accord-
ingly, the quasispecies structure, based on the resulting proviral
DNA, displayed 2 peaks. Most genomes comprising the second
peak are expected to contain premature stop codons (given
s 102) and are thus not likely to be packaged in progeny virions.
We therefore estimated f
 
as the mean ﬁtness of the portion of
the quasispecies under the ﬁrst peak. We found that f
  0:76,
using which in Eq. (1) along with other parameters employed in
our simulations (Supplementary material S1) yielded ac  0:815, in
close agreement with the value obtained from our simulations.
Next, we advanced the basic model of HIV dynamics to account
explicitly for A3G activity. The basic model has been employed
successfully to describe viral load changes in patients, derive
insights into disease pathogenesis, and assess treatment efﬁcacy
(Nowak and May, 2000; Perelson, 2002). In particular, it predicts
that persistent infection requires that the basic reproductive
number, R0, deﬁned as the number of cells infected by virions
produced from one infected cell in a wholly susceptible cell
population, be larger than unity (Nowak and May, 2000). Here,
we estimated ac as the minimum value of a at which R
t
0, the value
of R0 under treatment targeting the A3G–Vif axis, dropped below
unity (Supplementary material S4). We obtained
ac ¼ 1
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which because ∏si ¼ 1 1μh li
  
o103 simpliﬁed to ac  11=R0.
Using recent estimates of R06 (Stafford et al., 2000) and 8
(Ribeiro et al., 2010), derived from patient data during acute infec-
tion, we obtained ac  0:830:875, again similar to our estimate
above.
Thus, using three approaches, namely, stochastic simulations of
viral evolution, population genetics-based mathematical modeling
and viral dynamics-based mathematical modeling, we estimated that
when over approximately 80% of the progeny virions incorporated
A3G, productive HIV-1 infection was rendered unsustainable.
Discussion
Lethal mutagenesis holds promise as a novel strategy for the
treatment of HIV-1 infection (Dapp et al., 2012; Lauring and
Andino, 2010; Mullins et al., 2011). Recognizing that A3G is a
natural mutagen of HIV-1 that is suppressed by Vif, the A3G–Vif
interaction is being targeted with the hope of unleashing the
mutagenic potential of A3G. A recent multi-scale model (Hosseini
and Mac Gabhann, 2012) has examined the relative merits of
suppressing Vif, upregulating A3G expression or activity, or block-
ing the interaction of Vif and A3G, representing different modes of
targeting the A3G–Vif axis employed by current drug candidates.
We recognized here that each of these modes would result
effectively in an increased fraction of budding virions incorporat-
ing A3G. Accordingly, we estimated the critical fraction of progeny
virions that must contain A3G in order to render productive HIV-1
infection unsustainable. We found the fraction to be approxi-
mately 0.8, yielding a quantitative guideline for strategies target-
ing the A3G–Vif axis.
Intriguingly, the critical fraction identiﬁed lies at the upper end
of the range 0.3–0.8 A3G units/virion observed experimentally
with fully functional Vif (Nowarski et al., 2008). Controlled
hypermutations may serve to increase viral diversity and poten-
tially accelerate viral adaptation (Berkhout and de Ronde, 2004;
Kim et al., 2010; Sadler et al., 2010; Wood et al., 2009). Indeed,
suppressing A3G has been suggested as a potential intervention
strategy that may restrict viral diversity and prevent immune
escape (Harris, 2008). If A3G incorporation increased beyond the
critical fraction, however, infection would be rendered unsustain-
able. Thus, for HIV-1 to derive the maximum beneﬁt from A3G, it
would have to maintain the level of A3G incorporation just below
the critical fraction, which is what Vif appears to accomplish. The
observed 0.3–0.8 A3G units/virion may thus be indicative of an
evolutionary optimum attained by HIV-1. We recognize that our
simulations yield the critical fraction of virions that must be
prevented by A3G from productively infecting cells and not the
number of A3G units that must be incorporated within a virion to
render it incapable of productive infection. In recent studies, the
presence of a single A3G catalytic unit per virion has been found
adequate to exert maximal antiviral activity, suggesting an “all-or-
nothing” mode of A3G action (Armitage et al., 2012; Browne et al.,
2009). The latter scenario remains to be fully established; sub-
lethal A3G activity has also been reported (Sadler et al., 2010).
Given that Vif drives the average number of A3G units down from
4–26 to 0.3–0.8 per virion, we may assume that with fully
functional Vif, a virion may typically carry at most 1 A3G unit.
Then, with the all-or-nothing scenario, the critical fraction in our
simulations would be equivalent to the corresponding average
number of A3G units per progeny virion. Whether the in vitro
estimate of 0.3–0.8 A3G units/virion (Nowarski et al., 2008),
obtained by inferences from measurements of deaminase activity
rather than direct protein quantiﬁcation, also holds in vivo
remains to be established.
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Fig. 2. A3G-induced suppression of productive infection. (A) Time-evolution of the population of infected cells predicted by our simulations for different values of a, the
fraction of progeny virions containing A3G, indicated. (B) The corresponding number of generations at which infection became extinct from the start of intervention
(symbols) ﬁt to an exponential proﬁle (line). (C) The structure of the quasispecies determined from (A) for a¼0.75 (dotted line) and a¼0.8 (solid line). For a¼0.8, the
realizations in which the infection was sustained were employed. Parameter values employed are mentioned in Supplementary material S1.
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Lethal mutagenesis has to be employed with caution because
suboptimal increase in the mutation rate may increase viral
diversity and facilitate drug resistance and immune escape. This
cautionary note has been sounded for intervention at the A3G–Vif
axis as well (Harris, 2008; Malim, 2009; Pillai et al., 2008; Smith,
2011). Indeed, A3G-induced development of drug resistance has
been observed in vitro (Kim et al., 2010; Mulder et al., 2008).
We speculate based on our simulations that targeting the A3G–Vif
axis may be much less fraught with the risk of enhancing viral
adaptability than strategies attempting to drive HIV-1 past its
error threshold. Our simulations suggest that the viral quasispecies
would remain compact upon increasing the fraction of virions
carrying A3G to the critical value; infection would be driven to
extinction without the signiﬁcant increase in diversity expected
upon crossing the error threshold. For instance, whereas the
quasispecies remained localized around Hamming classes 20
and 60 in our simulations (Fig. 2C), crossing the error threshold
would result in complete delocalization of the quasispecies yield-
ing a mean Hamming class of L=2 5000 (Tripathi et al., 2012).
In support, another modeling study has also estimated that A3G
would contribute marginally to the increase in mutations at
known drug resistance sites (Jern et al., 2009).
We recognize several limitations of our study. First, our
simulations did not consider viral reservoirs, such as latently
infected cells (Finzi et al., 1999), where the virus can reside long-
term without active replication. Our estimate of the critical
fraction is thus for suppression of productive infection. Second,
we did not consider hypermutations in the GA dinucleotide
context as well as other non-editing modes of A3G action against
HIV-1 (e.g., see Martin et al., 2011; Norman et al., 2011). Third, we
restricted our simulations to A3G, whereas other APOBEC family
members, particularly A3F, may also contribute to lethal viral DNA
editing and further compromise viral infectivity. Fourth, we
assumed that the initial viral pool comprised the ﬁttest genome
alone, whereas the viral quasispecies in the chronic phase of
infection, when intervention is likely to commence, is expected
to comprise a diverse pool of genomes with a lower mean ﬁtness,
and hence requiring lower A3G activity than estimated for
suppression of infection. Our estimate of the critical fraction is
thus conservative and may be treated as an upper bound on the
extinction threshold.
In conclusion, our study estimated the minimum fraction of
virions that must incorporate A3G to suppress productive infection
of HIV-1, presenting a quantitative guideline for strategies target-
ing the A3G–Vif axis.
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